Files in this item

FilesDescriptionFormat

application/pdf

application/pdfSherkowZettler-fin-1.pdf (337kB)
(no description provided)PDF

Description

Title:EpiPen, Patents, and Life and Death
Author(s):Sherkow, Jacob S.; Zettler, Patricia J.
Subject(s):patents
fda
combination product
drugs
device
epipen
emergency medicine
Abstract:Drug pricing disputes, while significant public health concerns, are not typically immediate life or death matters. But they may be for certain emergency medicines, medicines used for potentially lethal and rapidly onset illnesses or injuries. This is especially true for emergency drug-device combination products, like Mylan’s EpiPen, for which patients can bear a significant brunt of the products’ cost. Scholarly commentary on the controversy surrounding the pricing of Mylan’s EpiPen, however, has largely elided over this relationship among combination products, emergency medicine, and patient payment, often focusing instead on classic issues of antitrust and competition. This brief Essay explores how EpiPen’s pricing capacity is a function of a peculiar intersection of emergency medicine, FDA law and policy, and patents, and suggests areas of further analysis for other drug-device emergency combination products.
Issue Date:2021-08-20
Publisher:New York University School of Law
Citation Info:Jacob S. Sherkow & Patricia J. Zettler, EpiPen, Patents, and Life and Death, 96 NYU L. Rev. Online 164 (2021)
Genre:Article
Type:Text
Language:English
URI:http://hdl.handle.net/2142/110345
Date Available in IDEALS:2021-08-23


This item appears in the following Collection(s)

  • Illinois Research and Scholarship
    This is the default collection for all research and scholarship developed by faculty, staff, or students at the University of Illinois at Urbana-Champaign

Item Statistics